Expression of the ErbB Family of Receptor Tyrosine Kinases and Toll-like Receptor 4 on
Oral Squamous Cell Carcinoma Cells: A Preliminary Study
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Epidermal growth factor receptor (EGFR) and its three
related proteins are collectively known as an ErbB family of
receptor tyrosine kinases (RTKs). It comprises of four
distinct receptors: the EGFR (ErbB1/Her1), ErbB2
(neu/Her2), ErbB3 (Her3) and ErbB4 (Her4). It plays a
critical function in the homeostasis of epithelial cells. It also
drives cancer development.
Oral squamous cell carcinoma (OSCC) is considered the sixth
most common cancer. It has been reported that an
overexpression of EGFR correlated with progression and
poor prognosis in SCC of the tongue. Therefore, targeted
inhibition of EGFR is a promising approach to suppress
signal transduction pathways which control tumor cell
growth, proliferation, and resistance to apoptosis.
The role of bacteria in cancer, in particular initiation and
progression, is well known. It has been reported that TLR4
activation by lipopolysaccharide (LPS) results in resistance to
EGFR-targeted therapy in OSCC.
The overall goal of the study is to elucidate how oral bacteria
influence the clinical outcome of the EGFR-targeted therapy
in OSCC since the oral cavity harbors a diverse and complex
microbial community. In this presentation, we reported an
expression of ErbB family of RTKs and TLR 4 on OSCC cells.

Materials and Methods
OSCC cells
HSC-2, HSC-3, and HSC-4 human OSCC cells were
purchased from JCRB Cell Bank (Ibaraki, Osaka Japan).
They were maintained at 37°C, under 5% CO2 in Dulbecco’s
modified Eagle’s MEM medium supplemented with 10% fetal
bovine serum (FBS), penicillin (100 units/ml), streptomycin
(100 µg/ml) and L-glutamine (2 mM) (DME/10). For
viability assay, HSC-3 cells were seeded in 48-well plates at a
density of 1.0 x 105 cells per well in 1 ml of DME/10 medium
24 hours before the LPS challenge.
Analysis of Basal Expression Level of ErbB family
proteins and TLR4
HSC-2, HSC-3, and HSC-4 cells were stained with ErbB1,
ErbB2, ErbB3, ErbB4, or TLR4 for 60 min at 4°C. All
analyses were performed on a guava easyCyte 8HT, using the
InCyte 2.7.
Cell Viability Assay
The trypan blue exclusion test was used to determine the
number of viable cells using Countess™.

Results

ErbB1

ErbB2

ErbB3

ErbB4

TLR4

ErbB1

ErbB2

ErbB3

ErbB4

TLR4

HSC-2

HSC-3

ErbB1

HSC-4

HSC-3 numbers (x 106)

Background and Objectives

ErbB2

ErbB3

ErbB4

TLR4

Conclusion and Future Directions
All OSCC cells tested expressed ErbB1, ErbB2, and ErbB3. HSC-3 and
HSC-4 also expressed TLR4. As future directions, we will first examine
whether or not LPS stimulation affects ErbB family protein expression
(i.e., upregulation or downregulation). We hypothesized that the
receptors will be upregulated since HSC-3 cell proliferated in response
to LPS.
Unveiling the crosstalk between EGFR and TLR4 in
EGFR-targeted therapy in OSCC may potentially provide us with better
therapeutic approach to target EGFR.
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